Asahi Kasei ＜3407＞: 1030 yen (-20 yen)
decline. The acquisition of Caliditas, a Swedish pharmaceutical company, has been announced. All shares have been acquired through TOB, and it seems that the total acquisition amount is expected to be 173.9 billion yen. Cariditas is developing drugs for kidney disease in the US and elsewhere. On the company side, it seems that they are aiming for sales of 1 trillion yen in the pharmaceutical and medical device business in fiscal year 30. The final profit and loss of Cariditas for the fiscal year ending 23/12 is in deficit of about 6.8 billion yen, but future sales are expected to expand rapidly. Today, movements to be wary of increased financial burdens etc. are taking the lead.
Renova ＜9519＞: 1,029 yen (-89 yen)
A sharp decline. Nomura Securities continues to make “neutral” investment decisions, and the target stock price has been lowered from 1330 yen to 1000 yen. The rebound had been getting stronger over the day before, but it seems that it is being used as a trigger for return sales. Nomura Securities revised its EBITDA forecast downward from the fiscal year ending 25/3 to the fiscal year ending 26/3 because profit margins for biomass power generation have declined. Although the company plan is expected to be exceeded, it is said that there is little sense of undervaluation in stock prices. Expanding the effects of the partnership with Tokyo Gas is the key to the future.
Teijin ＜3401＞: 1527.5 yen (-80.5 yen)
A sharp decline. SMBC Nikko Securities downgraded investment decisions from “1” to “2,” and the target stock price was also lowered from 1850 yen to 1600 yen. Structural reforms and growth expectations for Aramid were anticipated, but expectations were factored into structural reforms to a certain extent, and it seems that profit margins for Aramid deteriorate drastically in the fiscal year ending 25/3 due to price declines. It seems that they are judging that the sense that stock prices are undervalued has disappeared in particular.
Mitsubishi Heavy ＜7011＞: 1301 yen (-56 yen)
The sharp decline continued. A new medium-term plan was announced the day before. As numerical targets, in addition to setting business profit of 450 billion yen or more (forecast for the fiscal year ending 25/3), ROE 12% or more (same 11.1%), etc. for the fiscal year ending 27/3, DOE has been adopted as a shareholder return policy, and an annual dividend of 26 yen (same 22 yen) is planned. It seems that the level is almost in line with market expectations, but it also seems that expectations for the mid-term budget have been raised beforehand, leading to a short-term sense of exhaustion.
KOKUSAI ＜6525＞: 4360 yen (+285 yen)
Significant continued growth. Nomura Securities has upgraded investment decisions from “neutral” to “buy,” and the target stock price has also been raised from 5,000 yen to 5450 yen. Stock prices have been sluggish since February due to a decline in order acceptance, a decline in gross profit margin, and supply-demand concerns associated with unlocking the lockup, etc., but bad materials have surfaced in terms of performance, and it seems that evaluations are being raised due to medium-term GAA structural sales expansion and high growth expectations due to NAND recovery. Also, there is a high possibility that an increase in shareholder returns will be realized after the fiscal year ending 26/3.
BlueMeme＜4069＞: 1205 yen (-56 yen)
It continued to decline drastically. It has been disclosed that the announcement of financial results for the fiscal year ending 24/3, which was scheduled to be disclosed on the 28th, will be postponed again to the 29th. Work was underway for the announcement, but it took time to finalize the financial results. Initially, it was scheduled to be announced on the 14th, but due to a review of the accounting policy for software license sales, it was postponed to the 28th because it took time for verification work by an audit firm, scrutinize the amount of impact on previous years, and determine whether corrections were necessary.
Qualypus (4894): 4520 yen (+120 yen)
The price has been high since listing. The Tokyo Stock Exchange has expanded the upper limit of the price limit to 2800 yen. The lower limit is 700 yen as usual, and the standard price is 4,400 yen. The high stop is 7200 yen, and the low stop is 3700 yen. Investment funds continue to flow in from the expectation that Qualyps will apply to the Ministry of Health, Labor, and Welfare for manufacturing and sales approval for the world's first iPS cell-derived cardiomyocyte sheet as early as June, and it seems that buying invites buying.
Truss OP ＜6696＞: 618 yen (+27 yen)
Significant backlash. It has been announced that they have received an order for a system development project from a business partner. The order amount is 0.29 million yen (excluding tax), and the contract due date is scheduled for May-July. Sales are scheduled for the 2nd quarter of the fiscal year ending 25/1, and are factored into full-year earnings forecasts. Truss On Product shares updated their year-to-date high the day before and rose to 705 yen, then dropped drastically until closing, and it seems that they are also buying in.